Therapy: is the attempted remediation of a health problem, usually following a diagnosis. In the medical field, it is usually synonymous with treatment.
-
The NCI's Therapeutically Applicable Research to Generate Effective Treatments (TARGET) is a comprehensive genomic characterization initiative to determine the molecular changes that drive th...
OCT 17, 2013 | 3:00 PM
C.E. CREDITS
Although genome-wide association studies (GWAS) have identified many single nucleotide polymorphisms (SNPs) associated with cancer, the contribution to risk of these variants is small, rende...
OCT 17, 2013 | 2:00 PM
C.E. CREDITS
Pancreatic cancer is the 4th most common cause of cancer deaths in the United States. Due to the aggressive nature of this cancer and the lack of biomarkers for early detection, the incidence...
OCT 17, 2013 | 11:00 AM
C.E. CREDITS
Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant...
OCT 17, 2013 | 10:00 AM
C.E. CREDITS
Prostate cancer epithelial cells depend on androgens for their survival. Because of this dependence, androgen deprivation therapy is the major treatment of advanced prostate cancer. Such ther...
Many drugs currently used for anti-cancer therapy demonstrate significant inter-individual variability that cannot be normalized using body weight or body surface area. There is an increasing...
OCT 17, 2013 | 7:00 AM
C.E. CREDITS
Recent data have confirmed the ability of cardiac troponin (cTn) measurements to identify those who are developing cardiotoxicity in response to potentially cardiotoxic chemotherapeutic agen...
The widespread adoption of precision medicine in oncology requires: a compendium of therapies targeting the genetic vulnerabilities of cancer; the diagnostic tools capable of generating a pr...
OCT 16, 2013 | 3:00 PM
C.E. CREDITS
While Melanoma is very curable and treatable when detected early, late stage melanoma has had a very poor outcome. In 2013, it is estimated that over 80,000 patients in the US will develop me...
OCT 16, 2013 | 2:00 PM
C.E. CREDITS
Non Small Cell Lung Cancer (NSCLC) is one of the most significant causes of cancer-related mortality worldwide. In about 6-7% of NSCLC, rearrangements involving the Anaplastic Lymphoma Kinase...
OCT 16, 2013 | 1:00 PM
C.E. CREDITS
While androgen deprivation therapy (ADT) remains the primary treatment modality for patients with metastatic prostate cancer (PCa), treatment is uniformly marked by progression to castration-...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Th...
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, a...
OCT 16, 2013 | 9:00 AM
C.E. CREDITS
It is now appreciated that breast cancer is not a single disease, but instead is a spectrum of tumor subtypes with distinct cellular origins, somatic changes and somewhat predictable clinical...
OCT 16, 2013 | 7:00 AM
C.E. CREDITS
With the rapid rise in the number of therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision-making, emphasizing the nee...
OCT 16, 2013 | 7:00 AM
C.E. CREDITS
The adjuvant therapy of choice for superficial bladder cancer is the intravesical instillation of live Mycobacterium bovis Bacillus Calmette-Guerin (BCG). In spite of the fact that this thera...
The knowledge of molecular alterations involved in colon carcinoma (CRC) and non-small-cell lung carcinoma (NSCLC) has significantly increased in the past few years. Molecular subgroups of t...
AUG 22, 2013 | 3:00 PM
C.E. CREDITS
The use of ultrahigh throughput diagnostic tests that determine genetic sequence variation to guide patient care is rapidly expanding, fueled by the enormous growth in sequencing platform dev...
Since the introduction of second-generation DNS sequencing technologies in 2007, the cost of genome sequencing has been consistently by 33% per quarter, with the $1000 genome arriving in 2012...